193 Diagnostic utility of molecular and imaging biomarkers 2 Table 42. Baseline characteristics of included studies investigating microRNAs reference country study design ni, test set tested miRNAs upregulated microRNAs in test set downregulated microRNAs in test set Agretti 2012 Italy PS 88 in vivo FNAC samples: 45 benign, 43 PTC miR-146b, -155, -187, -197, -221, -222, -224 miR-146b, -155, -187, -221, -222, -224 none Keutgen 2012 USA PS 29 ex vivo indeterminate FNAC samples: 2 HN, 13 FA, 4 PTC, 8 FVPTC, 2 FTC miR-21, -146b, -181, -197, -222, -328 miR-21, -197, -222, -328 none Shen 2012 USA RS 60 FNAC samples: 16 histopathologically benign, 44 histopathologically malignant (25 with atypical cytology of undetermined significance) miR-30d, -138, -146b, -187, -197, -221, -302c, -346 miR-146b, -187, -221 miR-30d Vriens 2012 USA RS 104 thyroid tissue samples: 7 normal thyroid, 14 HN, 12 FVPTC, 8 PTC, 15 FA, 12 FTC, 12 HCA, 20 FTC-OV, and 4 ATC miR-100, -125b, -138, -149, -550, -564, -584, -628-3p, -635, -768-30 none miR-100, -125b, -138, -768-3p Labourier 2015 USA RS 529 cases: training set of 240 surgical specimens, case-control set of 54 surgical tissues and 235 preoperative FNAC samples miR-29b-1-5p, -31-5p, -138-1-3p, -1395p, -146b-5p, -155, -204-5p, -222-3p, -375, -551-3p n.s. n.s. Rossi 2016 Italy PS 35 FNAC samples: 13 benign, 13 FN and 11 malignant thyroid nodules miR-10b, -92a, -221,-222, -375 miR-375 none ATC: anaplastic carcinoma. FA: follicular adenoma. FTC: follicular thyroid carcinoma. FTC-OV: FTC, oncocytic variant (Hürthle cell carcinoma). FVPTC: papillary thyroid carcinoma, follicular variant. HN: hyperplastic nodule. ni: number of indeterminate thyroid nodules included in our analysis. n.s.: not specified. PS: prospective. PTC: papillary thyroid carcinoma. RS: retrospective.
RkJQdWJsaXNoZXIy MTk4NDMw